Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation

Autor: Kiyonao Nakamura, Kenji Takayama, Takashi Mizowaki, Shusuke Akamatsu, Takashi Kobayashi, Takahiro Inoue, Toshinari Yamasaki, Rihito Aizawa, Osamu Ogawa
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Male
medicine.medical_specialty
Intensity-modulated radiation therapy
medicine.medical_treatment
Urinary system
Urology
Salvage therapy
Androgen deprivation therapy
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Surgical oncology
medicine
Humans
Cumulative incidence
Prospective Studies
Aged
Retrospective Studies
Salvage Therapy
business.industry
Short-term androgen deprivation therapy
Prostatic Neoplasms
Early salvage androgen deprivation therapy
Androgen Antagonists
Hematology
General Medicine
Middle Aged
medicine.disease
Prognosis
Neoadjuvant Therapy
Radiation therapy
Survival Rate
030104 developmental biology
Oncology
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Surgery
Original Article
Radiotherapy
Intensity-Modulated
business
Adjuvant
Unfavorable risk
Zdroj: International Journal of Clinical Oncology
ISSN: 1437-7772
1341-9625
Popis: Background The optimal timing of salvage androgen deprivation therapy (ADT) following definitive radiation therapy for prostate cancer (PCa) is unknown. This study evaluated the efficacy of early initiation of salvage-ADT (S-ADT) based on predetermined timing among patients with unfavorable PCa treated with high-dose intensity-modulated radiation therapy (IMRT). Materials and methods High-risk (HR) and very-high-risk (VHR) PCa patients treated with IMRT at our institution between September 2000 and December 2010 were analyzed retrospectively. Treatment consisted of high-dose IMRT (78 Gy/39 fractions) combined with 6 months of neoadjuvant-ADT (NA-ADT). S-ADT was initiated when prostate-specific antigen levels exceeded 4.0 ng/mL. Results In total, 268 (184 HR and 84 VHR) patients were analyzed. The median follow-up period was 114.4 months. The 10-year overall survival (OS), PCa-specific survival (PCSS), biochemical failure (BF), and clinical failure (CF) rates were 82.8%, 97.1%, 27.3%, and 12.8% among the HR PCa patients and 79.4%, 87.9%, 56.2%, and 26.7% among the VHR PCa patients (p = 0.839, = 0.0377
Databáze: OpenAIRE
Externí odkaz: